PTC Therapeutics, established in 1998, is a science-driven, global biopharmaceutical company that is researching new treatments for rare diseases by leveraging its platform technologies in gene therapy and other leading-edge biosciences. To deliver on its promise of developing transformative treatments for patients, PTC acquired a manufacturing facility in Hopewell in June of 2020. The 240,000-square-foot space was strategically selected by PTC due to its existing biologic manufacturing capabilities, providing the team with a head start on renovating in order to produce materials for various pre-clinical and clinical programs. PTC’s new Hopewell facility is also close to the company’s existing manufacturing site in nearby Bridgewater. After acquiring the property, the company hired CRB to oversee the design and Lendlease Construction to build out the $11.5 million renovations to the structure in order to meet its unique production needs. Creating 13 construction jobs, the new manufacturing facility was dedicated in October of 2021. Employing more than 180 full-time workers, the facility represents a welcome expansion for the area. New Jersey Economic Development Authority Chief Executive Officer Tim Sullivan, speaking at the facility’s ribbon-cutting, noted the development helps to “bring more vibrancy, dynamism, activity and jobs to New Jersey.” PTC is being recognized for helping to solidify New Jersey’s leadership position in the global biopharma ecosystem. As an employer of 1,200 workers located in more than 20 countries around the world, PTC, which is headquartered in South Plainfield, continues to call New Jersey its corporate home.
Plymouth Meeting, PA
South PlainfieldRelated Articles: